Cost-effectiveness of Helicobacter pylori test and eradication versus upper gastrointestinal series versus endoscopy for gastric cancer mortality and outcomes in high prevalence countries

References

• World Cancer Research Fund International. Stomach Cancer Statistics. 2018. [cited 2019 May 26]. https://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/stomach-cancer-statistics
   Google Scholar
• National Cancer Center. Cancer Statistics in Japan. 2018 [cited 2019 May 26]. https://ganjoho.jp/reg_stat/statistics/dl/index.html#incidence4pref [Japanese].
   Google Scholar
• Wang C, Nishiyama T, Kikuchi S, et al. Changing trends in the prevalence of H. pylori infection in Japan (1908-2003): a systematic review and meta-regression analysis of 170,752 individuals. Sci Rep. 2017;7:15491.
   PubMed Web of Science ®Google Scholar
• International Agency for Research on Cancer, World Health Organization. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. In: IARC Working Group Report. Volume 8. 2014 [cited 2019 May 26]. http://www.gastro-health-now.org/wp/wp-content/uploads/2014/09/WHO-IARC-Report-2014.pdf
   Google Scholar
• Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection: the Maastricht IV/Florence Consensus Report. Gut. 2012;61:646–664.
   PubMed Web of Science ®Google Scholar
• Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378:1085–1095.
   PubMed Web of Science ®Google Scholar
• Kabir S. Effect of Helicobacter pylori eradication on incidence of gastric cancer in human and animal models: underlying biochemical and molecular events. Helicobacter. 2009;14:159–171.
   PubMed Web of Science ®Google Scholar
• Davies R, Crabbe D, Roderick P, et al. A simulation to evaluate screening for Helicobacter pylori infection in the prevention of peptic ulcers and gastric cancers. Health Care Manag Sci. 2002;5:249–258.
   PubMedGoogle Scholar
• Sugano K, Osawa H, Satoh K. Clinical management of Helicobacter pylori–the Japanese perspective. Dig Dis. 2014;32:281–289.
   PubMed Web of Science ®Google Scholar
• Doorakkers E, Lagergren J, Engstrand L, et al. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018;0:1–5.
   Google Scholar
• Ford AC, Forman D, Hunt R, et al. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2015;7:CD005583.
   Google Scholar
• Bae SE, Choi KD, Choe J, et al. The effect of eradication of Helicobacter pylori on gastric cancer prevention in healthy asymptomatic populations. Helicobacter. 2018;23:e12464.
   PubMed Web of Science ®Google Scholar
• Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001;49:347–353.
   PubMed Web of Science ®Google Scholar
• Kamangar F, Dawsey SM, Blaser MJ, et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst. 2006;98:1445–1452.
   PubMed Web of Science ®Google Scholar
• Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62:676–682.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507–513.
   PubMed Web of Science ®Google Scholar
• Lee YC, Chiang TH, Liou JM, et al. Mass eradication of Helicobacter pylori to prevent gastric cancer: theoretical and practical considerations. Gut Liver. 2016;10:12–26.
   PubMed Web of Science ®Google Scholar
• Doorakkers E, Lagergren J, Engstrand L, et al. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a Western population. Gut. 2018;67:2092–2096.
   PubMed Web of Science ®Google Scholar
• Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104:488–492.
   PubMed Web of Science ®Google Scholar
• Fock KM, Talley N, Moayyedi P, et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol. 2008;23:351–365.
   PubMed Web of Science ®Google Scholar
• Talley NJ, Fock KM, Moayyedi P. Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol. 2008;103:510–514.
   PubMed Web of Science ®Google Scholar
• Hamashima C. Current issues and future perspectives of gastric cancer screening. World J Gastroenterol. 2014;20:13767–13774.
   PubMed Web of Science ®Google Scholar
• Hamashima C, Systematic Review Group and Guideline Development Group for Gastric Cancer Screening Guidelines. Update version of the Japanese Guidelines for Gastric Cancer Screening. Jpn J Clin Oncol. 2018;48:673–683.
   PubMed Web of Science ®Google Scholar
• Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.
   Web of Science ®Google Scholar
• Lee HJ, Ock M, Kim KP, et al. Estimation of population-based utility weights for gastric cancer-related health states. Patient Prefe Adherence. 2018;12:909–918.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Ito M, Takata S, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–419.
   PubMed Web of Science ®Google Scholar
• Zhou HJ, Dan YY, Naidoo N, et al. A cost-effectiveness analysis evaluating endoscopic surveillance for gastric cancer for populations with low to intermediate risk. PLoS One. 2013;8:e83959.
   PubMed Web of Science ®Google Scholar
• Kosaka T, Endo M, Toya Y, et al. Long-term outcomes of endoscopic submucosal dissection for early gastric cancer: a single-center retrospective study. Dig Endosc. 2014;26:183–191.
   PubMed Web of Science ®Google Scholar
• Tai WC, Liang CM, Lee CH, et al. Seven-day nonbismuth containing quadruple therapy could achieve a grade "A" success rate for first-line Helicobacter pylori eradication. Biomed Res Int. 2015;2015:1.
   Web of Science ®Google Scholar
• IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer, IARC Working Group Report Volume 8, 2014.
   Google Scholar
• Hamashima C, Okamoto M, Shabana M, et al. Sensitivity of endoscopic screening for gastric cancer by the incidence method. Int J Cancer. 2013;133:653–659.
   PubMed Web of Science ®Google Scholar
• Igakutsushin-sya. National fee schedule and Medical insurance reimbursement table in Japan [in Japanese]. Tokyo: Igakutsushin-sya, 2017.
   Google Scholar
• Lansdorp-Vogelaar I, Sharp L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract Res Clin Gastroenterol. 2013;27:933–947.
   PubMed Web of Science ®Google Scholar
• Teng AM, Kvizhinadze G, Nair N, et al. A screening program to test and treat for Helicobacter pylori infection: cost-utility analysis by age, sex and ethnicity. BMC Infect Dis. 2017;17:156.
   PubMed Web of Science ®Google Scholar
• Roderick P, Davies R, Raftery J, et al. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess. 2003;7:1–86.
   PubMedGoogle Scholar
• Roderick P, Davies R, Raftery J, et al. Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. J Med Screen. 2003;10:148–156.
   PubMed Web of Science ®Google Scholar
• Xie F, Luo N, Lee HP. Cost effectiveness analysis of population-based serology screening and (13)C-Urea breath test for Helicobacter pylori to prevent gastric cancer: a Markov model. World J Gastroenterol. 2008;14:3021–3027.
   PubMed Web of Science ®Google Scholar
• Saito S, Azumi M, Muneoka Y, et al. Cost-effectiveness of combined serum anti-Helicobacter pylori IgG antibody and serum pepsinogen concentrations for screening for gastric cancer risk in Japan. Eur J Health Econ. 2018;19:545–555.
   PubMed Web of Science ®Google Scholar
• Kowada A. Cost-effectiveness of Helicobacter pylori screening followed by eradication treatment for employees in Japan. Epidemiol Infect. 2018;146:1834–1840.
   PubMed Web of Science ®Google Scholar
• Yeh JM, Hur C, Ward Z, et al. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut. 2016;65:563–574.
   PubMed Web of Science ®Google Scholar
• Bruce MG, Maaroos HI. Epidemiology of Helicobacter pylori infection. Helicobacter. 2008;13 Suppl 1:1–6.
   PubMed Web of Science ®Google Scholar
• Gisbert JP. The recurrence of Helicobacter pylori infection: incidence and variables influencing it. A critical review. Am J Gastroenterol. 2005;100:2083–2099.
   PubMed Web of Science ®Google Scholar